Author:
Yuasa Yasuhiro,Okitsu Hiroshi,Goto Masakazu,Edagawa Hiroshi,Mori Osamu,Tani Ryotaro,Tomibayashi Atsushi,Matsumoto Daisuke,Kuramoto Syunsuke,Osaki Kyosuke
Publisher
Springer Science and Business Media LLC
Reference22 articles.
1. Sobin L, Gospodarowicz M, Wittekind C. TNM classification of malignant tumours, 7th edn. NewYork: Wiley; 2009.
2. Ando N, Kato H, Igaki H, Shinoda M, Ozawa S, Shimizu H, et al. A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907). Ann Surg Oncol. 2012;19:68–74.
3. Yoshida T, Seike J, Miyoshi T, Yamai H, Takechi H, Yuasa Y, et al. Preoperative chemotherapy with weekly dDocetaxel plus low-dose cisplatin and 5-fluorouracil for stage II-III squamous cell carcinoma of the esophagus. Esophagus. 2010;7:95–100.
4. Watanabe M, Nagai Y, Kinoshita K, Saito S, Kurashige J, Karashima R, et al. Induction chemotherapy with docetaxel/cisplatin/5-fluorouracil for patients with node-positive esophageal cancer. Digestion. 2011;83:146–52.
5. Yokota T, Hatooka S, Ura T, Abe T, Takahari D, Shibata K, et al. Docetaxel plus 5-fluorouracil and cisplatin (DCF) induction chemotherapy for locally advanced borderline-resectable T4 esophageal cancer. Anticancer Res. 2011;31:3535–42.